Research indicates that tumor stem cells with CD44 + /α2β1hi/CD133+ phenotypes, derived from 40 patient biopsy samples, exhibit 3.7 times the self-renewal capability of CD133-negative cells (Vander Griend et al, 2008). Here, PROM1 is linked to neoplasm.